Immunic said fully enrolled Phase 3 ENSURE-1 and ENSURE-2 trials remain on track for December 2026 top-line data; third-quarter net loss was approximately $42.3 million, and $132.0 million cash is expected to fund operations into late 2027.
IMUX · Immunic, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Immunic expects ENSURE top-line data for vidofludimus calcium in December 2026. Cash and cash equivalents of approximately $132.0 million as of September 30, 2026 are expected to fund operations beyond twelve months.
Immunic expects two phase three relapsing MS trials, Insure One and Insure Two, to read out in December, potentially enabling an NDA filing, while initiating the Protect MS progressive-MS study.
Immunic expects Ensure 1 and Ensure 2 to read out in December; positive results could support an NDA filing and approval in relapsing multiple sclerosis, with filing targeted for the middle of next year.
Immunic is hosting a Progressive Multiple Sclerosis Research and Development Day webinar on November 5, 2026, from 12:30 p.m. to 2:00 p.m. ET via video conference, during which it plans to present.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| countries | 15 | Third Quarter 2026 | — |
| ENSURE-1 randomized patients | 1,121 | Third Quarter 2026 | — |
| ENSURE-2 randomized patients | 1,100 | Third Quarter 2026 | — |
| patients discontinued | 6.5% | through the January 27, 2026 data cutoff | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IMUX
this stock
Immunic, Inc.
|
$117.36M | — | — | — | 12.3% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 13, 2026
- This year
- 34
Immunic expects ENSURE top-line data for vidofludimus calcium in December 2026. Cash and cash equivalents of approximately $132.0 million as of September 30, 2026 are expected to fund operations beyond twelve months.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IMUX | -5.1% | +2.4% | -51.2% | -1.6% | +38.4% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | +0.3% | +8.6% | -45.5% | +3.7% | +33.4% |